Background Background Executive dysfunction is
Executive dysfunction is common after stroke and may impair longcommon after stroke and may impair longterm outcome.Remedies for this condition term outcome.Remedies for this condition are limited. are limited.
Aims Aims To examine the effect of
To examine the effect of antidepressants on executive function antidepressants on executive function after stroke. after stroke.
Method Method Forty-seven patients who had
Forty-seven patients who had had a stroke during the prior 6 months had a stroke during the prior 6 months received12 weeks of antidepressant received12 weeks of antidepressant treatment in double-blind placebotreatment in double-blind placebocontrolled fashion, followed by assessment controlled fashion, followed by assessment of executive function atthe end of of executive function atthe end of treatment and after 2 years. treatment and after 2 years.
Results

Results No significant group effect was
No significant group effect was found atthe end of treatment.However, found atthe end oftreatment.However, 21months after the end of treatmentthe 21months after the end of treatmentthe placebo group showed deterioration of placebo group showed deterioration of executive function, whereas the active executive function, whereas the active treatment group showed clear and treatment group showed clear and significant improvement independent of significant improvement independent of depressive symptoms ( depressive symptoms (F F¼12.1, d.f. 12.1, d.f.¼1,45, 1,45, P P¼ 0.001).
0.001).
Conclusions
Conclusions Antidepressant Antidepressant treatment fosters long-termimprovement treatment fosterslong-term improvement of executive function following stroke.This of executive function following stroke.This phenomenon is consistent with a phenomenon is consistent with a reorganisation of neuronal networks reorganisation of neuronal networks associated with prefrontal functions based associated with prefrontal functions based on modulation of monoaminergic on modulation of monoaminergic neurotransmission and the activity of neurotransmission and the activity of neurotrophins. neurotrophins.
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Executive functions are mental abilities that Executive functions are mental abilities that allow the individual to respond appropriallow the individual to respond appropriately to unfamiliar and complex situations ately to unfamiliar and complex situations and support several cognitive, emotional and support several cognitive, emotional and social capacities. Impairment of execuand social capacities. Impairment of executive functions occurs in the majority of tive functions occurs in the majority of stroke patients (Lesser stroke patients (Lesser et al et al, 1996), and , 1996) , and may slow rehabilitation and return to premay slow rehabilitation and return to premorbid levels of psychosocial adjustment. morbid levels of psychosocial adjustment.
Antidepressant treatment improves outAntidepressant treatment improves outcome following stroke, independently of come following stroke, independently of depression. Nortriptyline and fluoxetine depression. Nortriptyline and fluoxetine improve activities of daily living (Narushiimprove activities of daily living (Narushima & Robinson, 2003) and mortality ma & Robinson, 2003) and mortality (Jorge (Jorge et al et al, 2003) , and sertraline improves , 2003), and sertraline improves morbidity (Rasmussen morbidity (Rasmussen et al et al, 2003) . Anti-, 2003) . Antidepressants may exert outcome-improving depressants may exert outcome-improving effects on the brain in at least two ways: effects on the brain in at least two ways: one is through modulation of corticalone is through modulation of corticalstriato-pallido-thalamo-cortical pathways striato-pallido-thalamo-cortical pathways subsequent to action on the raphe nuclei, subsequent to action on the raphe nuclei, locus ceruleus and ventral tegmental area locus ceruleus and ventral tegmental area (Alexopoulos (Alexopoulos et al et al, 2000) ; another is , 2000); another is through reorganisation of neural circuitry through reorganisation of neural circuitry favoured by their activity on brain-derived favoured by their activity on brain-derived neurotrophic factor (BDNF) (Saarelainen neurotrophic factor (BDNF) (Saarelainen et al et al, 2003 (Saarelainen et al et al, ). , 2003 . This evidence prompted our study hyThis evidence prompted our study hypothesis that antidepressants improve fronpothesis that antidepressants improve frontal executive function following stroke. tal executive function following stroke. This hypothesis has not been tested before. This hypothesis has not been tested before. The positive effect of treatment with antiThe positive effect of treatment with antidepressants on the cognitive abilities of olddepressants on the cognitive abilities of older adults (Allard er adults (Allard et al et al, 2003) and the , 2003) and the identification of similar mechanisms of exidentification of similar mechanisms of executive deficit in late life and stroke (Coffey ecutive deficit in late life and stroke (Coffey et al et al, 1988 , 1988a a, ,b b) further supported the ) further supported the rationale behind this study. We predicted rationale behind this study. We predicted that antidepressant treatment would imthat antidepressant treatment would improve executive dysfunction independently prove executive dysfunction independently of depression. of depression.
METHOD METHOD
Patient selection Patient selection
Data allowing examination of the study Data allowing examination of the study hypothesis were collected during a doublehypothesis were collected during a doubleblind placebo-controlled treatment study blind placebo-controlled treatment study of post-stroke depression (Robinson of post-stroke depression (Robinson et al et al, , 2000 Patients taking antidepressants disconPatients taking antidepressants discontinued them for a 2-week wash-out period tinued them for a 2-week wash-out period before the study. Written consent was before the study. Written consent was obtained in accordance with institutional obtained in accordance with institutional review board requirements. Ninety-two review board requirements. Ninety-two patients entered the double-blind placebopatients entered the double-blind placebocontrolled phase and 69 completed it controlled phase and 69 completed it (Fig. 1) . (Fig. 1) .
After completing the treatment phase, After completing the treatment phase, seven patients refused to repeat the assessseven patients refused to repeat the assessment. Fifteen patients developed complicament. Fifteen patients developed complications and were excluded. In the active tions and were excluded. In the active treatment group, one patient developed treatment group, one patient developed Parkinson's disease, one had a transient cerParkinson's disease, one had a transient cerebrovascular ischaemic event just before the ebrovascular ischaemic event just before the evaluation and five experienced seizures. In evaluation and five experienced seizures. In the placebo group, one patient developed the placebo group, one patient developed psychosis, two had a stroke, and five psychosis, two had a stroke, and five experienced seizures. All patients who experienced seizures. All patients who developed seizures took anticonvulsants. developed seizures took anticonvulsants. There was no significant group difference There was no significant group difference in the frequency of complications in the frequency of complications ( (w w 2 2 ¼3.04, 3.04, P P¼0.08). Clinical and back-0.08). Clinical and background variables of patients not included ground variables of patients not included in the analysis were not significantly differin the analysis were not significantly different from those of participants included in ent from those of participants included in the analyses. Data from 47 patients were the analyses. Data from 47 patients were analysed, 30 of these patients were treated analysed, 30 of these patients were treated with either nortriptyline ( with either nortriptyline (n n¼11) or fluoxe-11) or fluoxetine ( tine (n n¼19), and 17 received placebo.
19), and 17 received placebo.
Treatment protocol Treatment protocol
Patients were randomly assigned to 12 Patients were randomly assigned to 12 weeks of either fluoxetine, nortriptyline or weeks of either fluoxetine, nortriptyline or placebo, unless there was a definite contraplacebo, unless there was a definite contraindication. Nortriptyline was chosen beindication. Nortriptyline was chosen because it is reported to be effective in postcause it is reported to be effective in poststroke depression (Lipsey stroke depression (Lipsey et al et al, 1984) ; , 1984); fluoxetine was chosen because it is a comfluoxetine was chosen because it is a commonly used selective serotonin reuptake inmonly used selective serotonin reuptake inhibitor with the advantage of a long halfhibitor with the advantage of a long halflife. Nortriptyline was not given to patients life. Nortriptyline was not given to patients with cardiac abnormalities, and fluoxetine with cardiac abnormalities, and fluoxetine was contraindicated in patients with was contraindicated in patients with intracerebral haemorrhage. Eight patients intracerebral haemorrhage. Eight patients had a contraindication to nortriptyline had a contraindication to nortriptyline and nine to fluoxetine: these patients were and nine to fluoxetine: these patients were randomly reassigned to the alternative acrandomly reassigned to the alternative active medication or to placebo. Thus, 85% tive medication or to placebo. Thus, 85% of the patients were randomly assigned to of the patients were randomly assigned to nortriptyline, fluoxetine or placebo. All panortriptyline, fluoxetine or placebo. All patients were randomly assigned to either actients were randomly assigned to either active or placebo medication. tive or placebo medication.
The dosages of nortriptyline were The dosages of nortriptyline were 25 mg per day for the first week, 50 mg 25 mg per day for the first week, 50 mg per day for weeks 2 and 3, then 75 mg per per day for weeks 2 and 3, then 75 mg per day for weeks 4-6 and 100 mg per day for day for weeks 4-6 and 100 mg per day for the final 6 weeks. Dosages of fluoxetine the final 6 weeks. Dosages of fluoxetine were 10 mg per day for the first 3 weeks, were 10 mg per day for the first 3 weeks, 20 mg per day for weeks 4-6, then 30 mg 20 mg per day for weeks 4-6, then 30 mg per day for weeks 7-9 and 40 mg per day per day for weeks 7-9 and 40 mg per day for the final 3 weeks. In nine patients the for the final 3 weeks. In nine patients the dosages had to be decreased owing to dosages had to be decreased owing to severe side-effects; five were being treated severe side-effects; five were being treated with nortriptyline and four with fluoxetine. with nortriptyline and four with fluoxetine. Reduction of dosage was achieved in douReduction of dosage was achieved in double-blind fashion. All the patients were fully ble-blind fashion. All the patients were fully compliant with their medication regimen compliant with their medication regimen throughout the treatment period. After throughout the treatment period. After completion of the treatment phase of the completion of the treatment phase of the study, all the medications were discontinued. study, all the medications were discontinued.
Assessment Assessment
The initial neuropsychological examination The initial neuropsychological examination took place after the completion of the 12-took place after the completion of the 12-week double-blind phase. This was folweek double-blind phase. This was followed by a second evaluation 21 months lowed by a second evaluation 21 months after the end of active treatment. after the end of active treatment.
The neurological examination was conThe neurological examination was conducted by a neurologist using the National ducted by a neurologist using the National Institutes of Health (NIH) Stroke Scale Institutes of Health (NIH) Stroke Scale (Brott (Brott et al et al, 1989) . Severity of depression , 1989). Severity of depression was assessed using the 17-item version of was assessed using the 17-item version of the Hamilton Rating Scale for Depression the Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960 
Neuroimaging Neuroimaging
Computerised tomography or magnetic Computerised tomography or magnetic resonance scans were obtained and evaluresonance scans were obtained and evaluated for anatomical location and lesion ated for anatomical location and lesion volume by a neuroradiologist or a neurolovolume by a neuroradiologist or a neurologist unaware of the psychiatric findings. Legist unaware of the psychiatric findings. Lesion volume was estimated using the ratio sion volume was estimated using the ratio of the largest cross-sectional area of the of the largest cross-sectional area of the lesion to the area of the brain slice that lesion to the area of the brain slice that included the body of the lateral ventricles included the body of the lateral ventricles (Robinson (Robinson et al et al, 1986) . , 1986).
Statistical analysis Statistical analysis
Between-group comparisons were made Between-group comparisons were made using means, standard deviations and using means, standard deviations and repeated-measures analysis of variance repeated-measures analysis of variance (ANOVA). Frequency distributions were (ANOVA). Frequency distributions were compared using the chi-squared test. Indicompared using the chi-squared test. Individual executive function scores were transvidual executive function scores were transformed into standardised formed into standardised z z scores which scores which were combined into an 'executive index'. were combined into an 'executive index'. The follow-up executive index scores were The follow-up executive index scores were based on based on z z scores calculated using the basescores calculated using the baseline means and standard deviations. line means and standard deviations. Changes between the initial and follow-up Changes between the initial and follow-up measures were evaluated by change scores, measures were evaluated by change scores, where positive scores showed improvement where positive scores showed improvement and negative scores showed deterioration. and negative scores showed deterioration. Multiple linear regression was used to exMultiple linear regression was used to examine the potential contribution of clinical amine the potential contribution of clinical factors to executive improvement. All tests factors to executive improvement. All tests were two-tailed and significance was set were two-tailed and significance was set at at P P5 50.05. 0.05.
RESULTS RESULTS
Patient characteristics, Patient characteristics, neurological and radiological neurological and radiological findings findings
There was no statistically significant group There was no statistically significant group difference in background characteristics difference in background characteristics and demographic data (Table 1) . During and demographic data (Table 1) . During the 21-month post-treatment period, one the 21-month post-treatment period, one patient in the active treatment group patient in the active treatment group refused to participate, two complained of refused to participate, two complained of side-effects, and four died; in the placebo side-effects, and four died; in the placebo 2 61 2 61 AUTHOR'S PROOF AUTHOR'S PROOF group three patients refused follow-up evagroup three patients refused follow-up evaluations and one died. Thus, a total of 36 luations and one died. Thus, a total of 36 patients completed all evaluations. There patients completed all evaluations. There was no significant group difference in rates was no significant group difference in rates of withdrawal. The background variables of withdrawal. The background variables of patients who completed the follow-up of patients who completed the follow-up neuropsychological evaluations were not neuropsychological evaluations were not significantly different from those of patients significantly different from those of patients who did not complete them. who did not complete them.
In the period between the initial and In the period between the initial and follow-up evaluations, some patients were follow-up evaluations, some patients were given antidepressants by their treating phygiven antidepressants by their treating physicians. Type, dosage and duration of all sicians. Type, dosage and duration of all prescribed medications were recorded. The prescribed medications were recorded. The frequency and the duration of antidepresfrequency and the duration of antidepressant treatment in the two groups were not sant treatment in the two groups were not significantly different (Table 1) . Additionsignificantly different (Table 1) . Additionally, there was no significant group differally, there was no significant group difference in MMSE scores at the initial ence in MMSE scores at the initial evaluation (active treatment, mean evaluation (active treatment, mean¼27.5, 27. 25.6, s.d.¼0.95; 0.95; P P¼0.12). There was no significant group 0.12). There was no significant group difference in neurological and radiological difference in neurological and radiological variables (Table 2) . variables (Table 2) .
Executive index Executive index
At the completion of the treatment phase, At the completion of the treatment phase, executive performance showed no statistiexecutive performance showed no statistically significant between-group effect cally significant between-group effect ( (F F¼0.01, d.f. 0.01, d.f.¼1,45, 1,45, P P¼0.91). 0.91). A significant time-by-group interaction A significant time-by-group interaction was found between the initial and follow-up was found between the initial and follow-up evaluation. This was true for both efficacy evaluation. This was true for both efficacy analysis (i.e. analysing only patients who analysis (i.e. analysing only patients who completed the 24-month follow-up: completed the 24-month follow-up:
13.1, d.f.¼1,34, 1,34, P P¼0.001) and inten-0.001) and intention-to-treat (ITT) analysis (i.e. analysing tion-to-treat (ITT) analysis (i.e. analysing all patients who enrolled in the treatment all patients who enrolled in the treatment study, with missing data interpolated based study, with missing data interpolated based on actual observations using the last obseron actual observations using the last observation carried forward method: vation carried forward method: F F¼12.1, 12.1, d.f. d.f.¼1,45, 1,45, P P¼0.001). Patients given active 0.001). Patients given active treatment showed an improvement in extreatment showed an improvement in executive performance after 21 months, ecutive performance after 21 months, whereas patients given placebo showed a whereas patients given placebo showed a decline (Fig. 2) . decline (Fig. 2) .
There was no significant difference beThere was no significant difference between patients treated with nortriptyline tween patients treated with nortriptyline and fluoxetine. Paired and fluoxetine. .f.¼16, 16, P P¼0.02). All but one patient who received 0.02). All but one patient who received placebo showed deterioration of executive placebo showed deterioration of executive function 2 years after the initiation of the function 2 years after the initiation of the study. study.
Individual tests of executive Individual tests of executive function function
Participants' performance on the individual Participants' performance on the individual tests composing the executive index was tests composing the executive index was also examined (Fig. 3) . The COWA and also examined (Fig. 3) .01). The 0.01). The WAIS-R Similarities, Digit Span and Arith-WAIS-R Similarities, Digit Span and Arithmetic sub-tests showed the same direction metic sub-tests showed the same direction of change, but failed to reach statistical sigof change, but failed to reach statistical significance (Fig. 3) . nificance (Fig. 3) .
Multiple linear regression analysis Multiple linear regression analysis
Many factors may influence executive Many factors may influence executive function recovery in addition to antidepresfunction recovery in addition to antidepressant treatment. In order to examine the sant treatment. In order to examine the contribution of these potentially confoundcontribution of these potentially confounding factors, an exploratory stepwise regresing factors, an exploratory stepwise regression analysis was conducted including the sion analysis was conducted including the 2 6 2 2 6 2 AUTHOR'S PROOF AUTHOR'S PROOF following variables: active treatment or plafollowing variables: active treatment or placebo; severity of depressive symptoms at cebo; severity of depressive symptoms at baseline, on completion of the 3-month baseline, on completion of the 3-month placebo-controlled treatment phase and placebo-controlled treatment phase and after 2 years; age; gender; past and family after 2 years; age; gender; past and family psychiatric history; antidepressant treatpsychiatric history; antidepressant treatment during the 21-month follow-up ment during the 21-month follow-up period; presence of neurological impairperiod; presence of neurological impairment (motor, sensory or visual impairment (motor, sensory or visual impairments, or aphasia); lesion location (left ments, or aphasia); lesion location (left hemisphere, right hemisphere or brainhemisphere, right hemisphere or brainstem); lesion's proximity to the frontal pole stem); lesion's proximity to the frontal pole (i.e. relative distance between the frontal (i.e. relative distance between the frontal pole and the most rostral margin of the pole and the most rostral margin of the stroke lesion compared with the distance stroke lesion compared with the distance between the frontal and occipital poles); between the frontal and occipital poles); type (infarction or haemorrhage) and type (infarction or haemorrhage) and volume of lesion. volume of lesion. The final model predicting executive The final model predicting executive function consisted of active treatment or function consisted of active treatment or placebo, age, past psychiatric history, placebo, age, past psychiatric history, neurological impairment and total lesion neurological impairment and total lesion volume ( volume (F F(5,25) (5,25)¼3.91, 3.91, P P5 50.05). The only 0.05). The only factor that showed a significant indepenfactor that showed a significant independent effect was active treatment or placebo dent effect was active treatment or placebo ( (F F(1,25) (1,25)¼14.9, 14.9, P P5 50.01) ( Table 3) . 0.01) ( Table 3) .
DISCUSSION DISCUSSION
To our knowledge this is the first study to To our knowledge this is the first study to examine the effect of antidepressant examine the effect of antidepressant treatment on executive function following treatment on executive function following stroke. We found that 12 weeks of treatstroke. We found that 12 weeks of treatment, started within 6 months of the stroke, ment, started within 6 months of the stroke, exerted a positive effect on executive funcexerted a positive effect on executive function 21 months after treatment. The effect tion 21 months after treatment. The effect on cognitive function was independent of on cognitive function was independent of improvement in depression, was delayed improvement in depression, was delayed and was independent of intervening antiand was independent of intervening antidepressant treatment. The effect of antidepressant treatment. The effect of antidepressants on cognition did not extend to depressants on cognition did not extend to overall cognitive status as measured by the overall cognitive status as measured by the MMSE. MMSE.
Caveats Caveats
Before discussing these findings, some facBefore discussing these findings, some factors that might have influenced our results tors that might have influenced our results should be acknowledged. The majority of should be acknowledged. The majority of patients were high-school or college-edupatients were high-school or college-educated, White, married and belonged to cated, White, married and belonged to Hollingshead social class I to III (I is the Hollingshead social class I to III (I is the highest, V is the lowest). Therefore, the highest, V is the lowest). Therefore, the results may not be applicable to all stroke results may not be applicable to all stroke patients. As expected in studies examining patients. As expected in studies examining elderly people, follow-up evaluations could elderly people, follow-up evaluations could not be obtained for all patients. This may not be obtained for all patients. This may limit generalisation of our findings to limit generalisation of our findings to people willing or able to receive follow-up people willing or able to receive follow-up evaluations. Some patients were prescribed evaluations. Some patients were prescribed antidepressants during the naturalistic antidepressants during the naturalistic follow-up, and a small number of patients follow-up, and a small number of patients were reassigned to the alternative active were reassigned to the alternative active treatment or placebo for medical reasons; treatment or placebo for medical reasons; these factors might have introduced bias these factors might have introduced bias (although naturalistic antidepressant treat-(although naturalistic antidepressant treatment was not an independent predictor of ment was not an independent predictor of recovery). Finally, there was no neuropsyrecovery). Finally, there was no neuropsychological assessment to ensure the two chological assessment to ensure the two groups had equivalent levels of executive groups had equivalent levels of executive function prior to treatment; hence, despite function prior to treatment; hence, despite 2 6 3 2 6 3 AUTHOR'S PROOF AUTHOR'S PROOF Sim., Similarities sub-test). Significant group differences are shown for the COWA and PE tests (*); the other Sim., Similarities sub-test). Significant group differences are shown for the COWA and PE tests (*); the other tests showed either improvement or lack of deterioration in the active group but the difference between active tests showed either improvement or lack of deterioration in the active group but the difference between active and placebo treatment failed to reach statistical significance.The PE score is inverted to be consistent with the and placebo treatment failed to reach statistical significance.The PE score is inverted to be consistent with the other tests in the figure. other tests in the figure. randomisation, this might have influenced randomisation, this might have influenced the results. the results.
Clinical implications Clinical implications
The findings in this study have important The findings in this study have important implications for the neuropsychiatry of implications for the neuropsychiatry of stroke and rehabilitation medicine. Antidestroke and rehabilitation medicine. Antidepressants administered within 6 months of pressants administered within 6 months of stroke appear to improve long-term execustroke appear to improve long-term executive function outcome. This effect is twotive function outcome. This effect is twofold. As can be observed in Fig. 1 , antidefold. As can be observed in Fig. 1 , antidepressants both improve and prevent decline pressants both improve and prevent decline of executive function. How can this interof executive function. How can this interesting and clinically important phenomenon esting and clinically important phenomenon be explained? be explained?
Mechanisms Mechanisms
Frontal cortical^subcortical circuits Frontal cortical^subcortical circuits
Five frontal cortical-subcortical circuitsFive frontal cortical-subcortical circuitsmotor, oculomotor, dorsolateral prefronmotor, oculomotor, dorsolateral prefrontal, lateral orbital frontal, and anterior cintal, lateral orbital frontal, and anterior cingulate -subserve distinct motor and gulate -subserve distinct motor and cognitive abilities (Alexander cognitive abilities . , 1986). All circuits originate in the prefrontal corAll circuits originate in the prefrontal cortex, project to the striatum, synapse at the tex, project to the striatum, synapse at the level of the globus pallidus, substantia level of the globus pallidus, substantia nigra and thalamus, and finally return to nigra and thalamus, and finally return to the prefrontal cortex, forming closed loops the prefrontal cortex, forming closed loops -the cortical-striato-pallido-thalamo-corti--the cortical-striato-pallido-thalamo-cortical (CSPTC) pathway. The dorsolateral cal (CSPTC) pathway. The dorsolateral prefrontal, orbitofrontal, and anterior prefrontal, orbitofrontal, and anterior cingulate cortical circuits subserve both cingulate cortical circuits subserve both executive (Drewe, 1974; Baker executive (Drewe, 1974; Baker et al et al, , 1996) and affective functions (Baxter 1996) and affective functions (Baxter et et al al, 1985 (Baxter et et al al, , 1989 Drevets , 1985 Drevets , , 1989 Drevets et al et al, 1992; Baker , 1992; Baker et al et al, 1996; Elliott , 1996; Elliott et al et al, 1997) . They can , 1997). They can be modulated by the activity of monoamibe modulated by the activity of monoaminergic nuclei, including the raphe nuclei, nergic nuclei, including the raphe nuclei, the locus ceruleus and the ventral tegmental the locus ceruleus and the ventral tegmental area (Alexopoulos area (Alexopoulos et al et al, 2000) , which are , 2000), which are sites of action of antidepressant medicasites of action of antidepressant medications. Thus, the mechanism of executive tions. Thus, the mechanism of executive function recovery may be the modulation function recovery may be the modulation of monoaminergic nuclei exerting effects of monoaminergic nuclei exerting effects on CSPTC circuits. on CSPTC circuits.
Neurogenesis Neurogenesis
Another possible mechanism stems from Another possible mechanism stems from the association of chronic antidepressant the association of chronic antidepressant administration and neurogenesis. Neuroadministration and neurogenesis. Neurogenesis in the adult brain is generally genesis in the adult brain is generally thought to be restricted to germinal centres thought to be restricted to germinal centres in the subventricular zone and the hippoin the subventricular zone and the hippocampal/dentate gyrus (Peterson, 2002) . campal/dentate gyrus (Peterson, 2002) . Chronic administration of antidepressants Chronic administration of antidepressants enhances the development of immature enhances the development of immature neurons and promotes the survival and neurons and promotes the survival and function of adult neurons by enhancing function of adult neurons by enhancing BDNF and its receptor trkB, resulting in BDNF and its receptor trkB, resulting in functional and anatomical changes. Activfunctional and anatomical changes. Activation of BDNF and trkB receptor has been ation of BDNF and trkB receptor has been shown to be required for antidepressants shown to be required for antidepressants to induce behavioural effects (Saarelainen to induce behavioural effects (Saarelainen et al et al, 2003) , and has been posited as an ex-, 2003) , and has been posited as an explanation for the delayed treatment effect planation for the delayed treatment effect of antidepressants (Nibuya of antidepressants (Nibuya et al et al, 1995) . , 1995). Although there has been no demonstration Although there has been no demonstration of neurogenesis in the prefrontal cortex, of neurogenesis in the prefrontal cortex, chronic antidepressant treatment induces chronic antidepressant treatment induces activation of trkB receptor in the prefrontal activation of trkB receptor in the prefrontal cortex and is responsible for the sensitisacortex and is responsible for the sensitisation to the effects of BDNF (Saarelainen tion to the effects of BDNF (Saarelainen et al et al, 2003) . Neurotrophins, particularly , 2003) . Neurotrophins, particularly BDNF, have been shown to regulate neurite BDNF, have been shown to regulate neurite outgrowth (membrane-enclosed protruoutgrowth (membrane-enclosed protrusions of neuronal cell cytoplasm), synaptic sions of neuronal cell cytoplasm), synaptic plasticity and the selection of functional plasticity and the selection of functional connections in the central nervous system connections in the central nervous system in general (Katz & Shatz, 1996; McAllister in general (Katz & Shatz, 1996; McAllister et al et al, 1999) . Consistent with these findings , 1999). Consistent with these findings is the recent notion that chronic administrais the recent notion that chronic administration of antidepressants prevents stress-intion of antidepressants prevents stress-induced reduction of BDNF (Manji & duced reduction of BDNF (Manji & Duman, 2001; McEwen & Lasley, 2003; Duman, 2001; McEwen & Lasley, 2003; Brown Brown et al et al, 2004) . The finding in our , 2004). The finding in our study may make the study of neurotrostudy may make the study of neurotrophin-mediated mechanisms of improved exphin-mediated mechanisms of improved executive function worth pursuing in greater ecutive function worth pursuing in greater detail. detail.
Future studies Future studies
Our study has shown that early treatment Our study has shown that early treatment with antidepressants following stroke has with antidepressants following stroke has a remote positive effect on recovery and a remote positive effect on recovery and prevention of decline in executive function. prevention of decline in executive function. Monoaminergic modulation of frontal exMonoaminergic modulation of frontal executive functions and/or enhancement of ecutive functions and/or enhancement of neuronal plasticity and reorganisation of neuronal plasticity and reorganisation of limbic and frontal structures may underlie limbic and frontal structures may underlie this phenomenon. Our findings require this phenomenon. Our findings require confirmation in further studies, which confirmation in further studies, which might also explore whether any particular might also explore whether any particular antidepressant is to be preferred, and the antidepressant is to be preferred, and the optimal time, duration and dosage of optimal time, duration and dosage of treatment. treatment. are indebted to the patients of theYounkers Rehabiare indebted to the patients of the Younkers Rehabi- 
